56 search results for: expert insights

expert video

Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU

9 min

Dermatology

Exploration of the shared type 2 inflammation and neuroimmune axis dysfunction in AD, PN, and CSU leading to itch.

expert video

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

5 min

Dermatology

Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.

expert video

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

3 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

expert video

Unique Characteristics of Itch in AD, PN, and CSU – A Panel Discussion

5 min

Dermatology

Dr. Kim and Dr. Elmariah discuss how unique characteristics of itch in AD, PN, and CSU impact patients.

expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

5 min

Dermatology

Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation

expert video

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

5 min

Dermatology

Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.

Podcast

ADVENT On Air | Early Intervention and Disease Modification in Atopic Dermatitis

20 min

Dermatology

Prof. Thomas Bieber explores early intervention and disease modification in atopic dermatitis.

expert video

Type 2 Inflammation Contributes to Itch and Fibrois in PN

4 min

Dermatology

Join Dr. Kwatra outlining the micro itch cycle involving type 2 cell polarization and cytokines that directly affect fibroblasts to cause more immune dysregulation in PN.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region